Chemistry
Most GLP-1 receptor agonists are peptides, chains of amino acids that the stomach breaks down. Orforglipron is a small, non-peptide molecule that still activates the GLP-1 receptor. Because it is not a peptide, it is absorbed well from the gut without special additives. It was discovered by Chugai Pharmaceutical and developed by Eli Lilly.
Unlike oral semaglutide, which must be taken on an empty stomach with a small sip of water, the Foundayo label allows orforglipron to be taken at any time of day with or without food. The Wegovy pill label, by contrast, calls for an empty stomach, no more than 4 ounces of plain water and a 30-minute wait before eating.
Approval
The FDA approved orforglipron as Foundayo on April 1, 2026. It is indicated, with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition. It was reviewed under the FDA Commissioner's National Priority Voucher pilot program. The approval does not cover type 2 diabetes, which Lilly is studying separately.
Foundayo tablets come in strengths from 0.8 mg to 17.2 mg. The label starts low and raises the dose step by step at intervals of about a month (see titration).
Clinical trials
Orforglipron was tested in the ATTAIN phase 3 program in adults with obesity. ATTAIN-1 enrolled 3,127 adults with obesity and without diabetes for 72 weeks. In the ATTAIN-1 trial, adults with obesity and without diabetes on the highest dose of orforglipron studied lost 11.2% of their body weight on average after 72 weeks, vs. 2.1% on placebo. A second trial, ATTAIN-2, studied adults with obesity and type 2 diabetes, and the ACHIEVE trials studied orforglipron for blood sugar control in type 2 diabetes. The doses named in that trial differ from the strengths printed on the approved Foundayo tablets.
Side effects
The side effects of orforglipron are similar to those of other GLP-1 medicines: mainly nausea, constipation, diarrhea and vomiting, most often while the dose is rising. The Foundayo label carries the same boxed warning about thyroid C-cell tumors as injectable GLP-1 medicines. How the pill compares with weekly shots is covered on our pill vs. shot page.
See also
References
- Foundayo prescribing information, DailyMed (2026). dailymed.nlm.nih.gov
- FDA approves first new molecular entity under National Priority Voucher program, FDA press release, April 1, 2026. fda.gov
- Wharton et al., NEJM 2025 (ATTAIN-1). pubmed.ncbi.nlm.nih.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.